Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Study
Status: Ongoing
About
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC (BURAN)
Details
The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sponsor: Adlai Nortye Biopharma Co
NCT04338399
